HRP20201400T1 - Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa - Google Patents
Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa Download PDFInfo
- Publication number
- HRP20201400T1 HRP20201400T1 HRP20201400TT HRP20201400T HRP20201400T1 HR P20201400 T1 HRP20201400 T1 HR P20201400T1 HR P20201400T T HRP20201400T T HR P20201400TT HR P20201400 T HRP20201400 T HR P20201400T HR P20201400 T1 HRP20201400 T1 HR P20201400T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyridin
- methylmorpholin
- compound according
- methyl
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16156530 | 2016-02-19 | ||
| EP17705878.1A EP3416945B1 (en) | 2016-02-19 | 2017-02-17 | 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-one compounds useful for the treatment of cancer and diabetes |
| PCT/EP2017/053612 WO2017140841A1 (en) | 2016-02-19 | 2017-02-17 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201400T1 true HRP20201400T1 (hr) | 2020-11-27 |
Family
ID=55404645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201400TT HRP20201400T1 (hr) | 2016-02-19 | 2017-02-17 | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11077113B2 (enExample) |
| EP (1) | EP3416945B1 (enExample) |
| JP (3) | JP6997462B2 (enExample) |
| CN (3) | CN113754581A (enExample) |
| AU (3) | AU2017219846B2 (enExample) |
| CY (1) | CY1123285T1 (enExample) |
| DK (1) | DK3416945T3 (enExample) |
| ES (1) | ES2816376T3 (enExample) |
| HR (1) | HRP20201400T1 (enExample) |
| HU (1) | HUE050863T2 (enExample) |
| LT (1) | LT3416945T (enExample) |
| PL (1) | PL3416945T3 (enExample) |
| PT (1) | PT3416945T (enExample) |
| RS (1) | RS60898B1 (enExample) |
| RU (1) | RU2754664C2 (enExample) |
| SI (1) | SI3416945T1 (enExample) |
| SM (1) | SMT202000523T1 (enExample) |
| TW (1) | TWI721104B (enExample) |
| WO (1) | WO2017140841A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3416945T3 (pl) * | 2016-02-19 | 2020-12-28 | Sprint Bioscience Ab | Związki 6-arylo-4-(morfolin-4-ylo)-1h-pirydyn-2-onu przydatne w leczeniu nowotworu i cukrzycy |
| PT3416957T (pt) * | 2016-02-19 | 2020-09-25 | Sprint Bioscience Ab | Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes |
| HRP20220497T1 (hr) * | 2017-08-23 | 2022-05-27 | Sprint Bioscience Ab | Spoj morfolinilpiridona |
| IL302356A (en) * | 2017-08-23 | 2023-06-01 | Sprint Bioscience Ab | Pyridylpyridone compounds |
| PL3672948T3 (pl) * | 2017-08-23 | 2022-12-05 | Sprint Bioscience Ab | Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu |
| IL302355A (en) | 2017-08-23 | 2023-06-01 | Sprint Bioscience Ab | Azaindolylpyridone and diazaindolylpyridone compounds |
| WO2020008046A1 (en) | 2018-07-06 | 2020-01-09 | Sprint Bioscience Ab | Biomarker |
| US12540115B2 (en) * | 2019-08-21 | 2026-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
| JP2023550638A (ja) | 2020-11-25 | 2023-12-04 | デシフェラ・ファーマシューティカルズ，エルエルシー | ウイルス感染症の処置に使用するための、ｖｓｐ３４阻害剤としてのモルホリノ誘導体 |
| WO2022115549A1 (en) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of vps34 inhibitors |
| CN117083064A (zh) | 2020-11-25 | 2023-11-17 | 德西费拉制药有限责任公司 | 作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2316831T3 (da) | 2002-11-21 | 2013-06-10 | Novartis Ag | 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| PL2448940T3 (pl) | 2009-07-02 | 2014-10-31 | Sanofi Sa | Pochodne 6,7,8,9-tetrahydro-pirymido{1,2-a} pirymidyn-4-onu, ich wytwarzanie i zastosowanie farmaceutyczne |
| EA201390917A1 (ru) * | 2010-12-21 | 2013-12-30 | Новартис Аг | Дигетероарильные соединения в качестве ингибиторов vps34 |
| PT2655375E (pt) * | 2010-12-23 | 2015-03-02 | Sanofi Sa | Derivados de pirimidinona, sua preparação e sua utilização farmacêutica |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| FR2992314B1 (fr) * | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014145512A2 (en) * | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Potent small molecule inhibitors of autophagy, and methods of use thereof |
| JP6074043B2 (ja) * | 2013-08-29 | 2017-02-01 | 富士フイルム株式会社 | 新規なモルホリン誘導体またはその塩 |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| JP2017528486A (ja) * | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| PL3416945T3 (pl) * | 2016-02-19 | 2020-12-28 | Sprint Bioscience Ab | Związki 6-arylo-4-(morfolin-4-ylo)-1h-pirydyn-2-onu przydatne w leczeniu nowotworu i cukrzycy |
-
2017
- 2017-02-17 PL PL17705878T patent/PL3416945T3/pl unknown
- 2017-02-17 SI SI201730395T patent/SI3416945T1/sl unknown
- 2017-02-17 US US15/999,530 patent/US11077113B2/en active Active
- 2017-02-17 TW TW106105179A patent/TWI721104B/zh not_active IP Right Cessation
- 2017-02-17 EP EP17705878.1A patent/EP3416945B1/en active Active
- 2017-02-17 HU HUE17705878A patent/HUE050863T2/hu unknown
- 2017-02-17 AU AU2017219846A patent/AU2017219846B2/en active Active
- 2017-02-17 WO PCT/EP2017/053612 patent/WO2017140841A1/en not_active Ceased
- 2017-02-17 DK DK17705878.1T patent/DK3416945T3/da active
- 2017-02-17 LT LTEP17705878.1T patent/LT3416945T/lt unknown
- 2017-02-17 CN CN202111121825.5A patent/CN113754581A/zh active Pending
- 2017-02-17 CN CN202111123598.XA patent/CN113845472A/zh active Pending
- 2017-02-17 JP JP2018562701A patent/JP6997462B2/ja active Active
- 2017-02-17 RU RU2018131775A patent/RU2754664C2/ru active
- 2017-02-17 HR HRP20201400TT patent/HRP20201400T1/hr unknown
- 2017-02-17 PT PT177058781T patent/PT3416945T/pt unknown
- 2017-02-17 CN CN201780013738.3A patent/CN108698996B/zh active Active
- 2017-02-17 RS RS20201057A patent/RS60898B1/sr unknown
- 2017-02-17 ES ES17705878T patent/ES2816376T3/es active Active
- 2017-02-17 SM SM20200523T patent/SMT202000523T1/it unknown
-
2020
- 2020-08-27 CY CY20201100804T patent/CY1123285T1/el unknown
-
2021
- 2021-06-29 US US17/362,763 patent/US11633403B2/en active Active
- 2021-08-12 AU AU2021215234A patent/AU2021215234B2/en not_active Ceased
- 2021-12-08 JP JP2021199161A patent/JP7389504B2/ja active Active
-
2023
- 2023-03-09 US US18/181,046 patent/US20240050439A1/en not_active Abandoned
- 2023-10-13 AU AU2023248170A patent/AU2023248170A1/en not_active Abandoned
- 2023-11-10 JP JP2023192216A patent/JP2024016225A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7088983B2 (ja) | キナーゼ阻害剤としてのビアリールアミド化合物 | |
| AU2005245386B2 (en) | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| CA2858647C (en) | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b. | |
| CA2968633C (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
| KR102001745B1 (ko) | 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물 | |
| JP2019505594A5 (enExample) | ||
| JP6954566B2 (ja) | ２−多置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途 | |
| HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
| JP2009529047A5 (enExample) | ||
| AU2011216895A1 (en) | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | |
| ME02409B (me) | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja | |
| JP2020504747A5 (enExample) | ||
| AU2005295414A1 (en) | Heteroaryl-substituted alkyne compounds and method of use | |
| HRP20221454T1 (hr) | Piridinamin-piridonski i pirimidinamin-piridonski spojevi | |
| TWI891753B (zh) | 醯胺類化合物及其用途 | |
| JP2019505595A5 (enExample) | ||
| KR20180052702A (ko) | Perk 억제제로서의 1-페닐피롤리딘-2-온 유도체 | |
| JP2024528127A (ja) | 疼痛、特に神経障害性疼痛、並びに／又は、ａｔ２ｒ及び／若しくはａｔ２ｒ媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 | |
| JP2016540803A5 (enExample) | ||
| JP2019530708A5 (enExample) | ||
| US20230111910A1 (en) | Pd-1/pd-l1 inhibitor, preparation method therefor, and use thereof | |
| HRP20220571T1 (hr) | Spoj piridilpiridona | |
| HRP20161286T1 (hr) | Novi anti-invazivni spojevi | |
| CN107098884A (zh) | 一类取代的氨基吡啶类化合物及其制备和用途 |